Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.

MLA

Isnardi, Carolina A., et al. “Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.” The Journal of Rheumatology, vol. 49, no. 12, Dec. 2022, pp. 1385–89. EBSCOhost, https://doi.org/10.3899/jrheum.220469.

APA

Isnardi, C. A., Cerda, O. L., Landi, M., Cruces, L., Schneeberger, E. E., Montoro, C. C., Alfaro, M. A., Roldán, B. M., Gómez Vara, A. B., Giorgis, P., Ezquer, R. A., Crespo Rocha, M. G., Reyes Gómez, C. R., de Los Ángeles Correa, M., Rosemffet, M. G., Abarza, V. C., Pellet, S. C., Perandones, M., Reimundes, C., … Citera, G. (2022). Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines. The Journal of Rheumatology, 49(12), 1385–1389. https://doi.org/10.3899/jrheum.220469

Chicago

Isnardi, Carolina A, Osvaldo L Cerda, Margarita Landi, Leonel Cruces, Emilce E Schneeberger, Claudia Calle Montoro, María Agustina Alfaro, et al. 2022. “Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.” The Journal of Rheumatology 49 (12): 1385–89. doi:10.3899/jrheum.220469.